Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May 15;43(1):306.
doi: 10.1007/s00345-025-05691-5.

Platelet-rich plasma intra-plaque injections rapidly reduce penile curvature and improve sexual function in Peyronie's disease patients: results from a prospective large-cohort study

Giuseppe Dachille #  1 , Andrea Panunzio #  2 , Leonardo Bizzotto  3 , Maria Valeria D'Agostino  4 , Federico Greco  5   6 , Giuseppe Guglielmi  4 , Umberto Carbonara  4 , Marco Spilotros  4 , Claudia Citarella  7 , Angelo Ostuni  7 , Giuseppe Lucarelli  4 , Pasquale Ditonno  4 , Alessandro Tafuri  2   8 ; REACT (Research in Exploring Andrology, Cutting-edge Technologies) group
Affiliations

Platelet-rich plasma intra-plaque injections rapidly reduce penile curvature and improve sexual function in Peyronie's disease patients: results from a prospective large-cohort study

Giuseppe Dachille et al. World J Urol. .

Abstract

Purpose: To investigate efficacy and safety of platelet-rich plasma (PRP) intra-plaque injections in Peyronie's disease (PD) patients.

Methods: Three injections of 6 mL PRP were performed two weeks apart. Patients were evaluated at baseline (T0, first injection), after two weeks (T1, second injection), and four weeks after the third injection (T2). The curvature angle of the erect penis, plaque size, dedicated sexual function questionnaires (PD questionnaire-PDQ, and International Index of Erectile Function five-items - IIEF-5) scores, and adverse events/side effects were evaluated.

Results: Overall, 72 patients were included. Median age was 60 years, and median BMI was 23.1 kg/m2. Plaques were more frequently located at the middle third of the penis (n = 43); penile curvature direction was more frequently dorsal (n = 45). During follow up median plaque size decreased from 11.1 mm at T0 to 8.2 mm at T2 (p = 0.004), and median penile curvature decreased from 50.0° at T0 to 40.0° at T2 (p < 0.001). At the same timepoints, a statistically significant reduction was observed for all the three domains of the PDQ (PDQ1:p = 0.006, PDQ2:p = 0.002, PDQ3:p < 0.001), but not for the IIEF-5 (p = 0.3). At univariable linear regression analysis, testing the association between BMI and median penile curvature difference from the first and last evaluation, a tendency towards statistical significance was observed (β = -1.28, p = 0.055). No adverse events/side effect were registered.

Conclusion: PRP is a safe and effective treatment option in men with PD, rapidly reducing plaques size and penile curvature angle, thus positively influencing sexual function. The higher the BMI the lower benefit might be derived from PRP injection.

Keywords: Body mass index; Penile curvature; Penile induration; Peyronie’s disease; Platelet rich plasma; Regenerative medicine.

PubMed Disclaimer

Conflict of interest statement

Declarations:. Conflict of interest: The authors declare no competing interests. Ethical approval: The study was performed in line with the principles of the Declaration of Helsinki. The study was approved by the Ethical Committee of the University Hospital of Bari (Policlinico di Bari – Azienda Ospedaliero Universitaria Consorziale Policlinico, Bari, Italy—study n. 6720, protocol n. 0012112). All patients signed an informed consent for data collection, analysis and publication. Consent to participate: All patients signed an informed consent for data collection, analysis and publication.

Similar articles

See all similar articles

References

    1. Al-Thakafi S, Al-Hathal N (2016) Peyronie’s disease: a literature review on epidemiology, genetics, pathophysiology, diagnosis and work-up. Transl Androl Urol 5:280–289. https://doi.org/10.21037/tau.2016.04.05 - DOI - PubMed - PMC
    1. Stuntz M, Perlaky A, des Vignes F et al (2016) The prevalence of Peyronie’s disease in the United States: a population-based study. PLoS ONE 11:e0150157. https://doi.org/10.1371/journal.pone.0150157 - DOI - PubMed - PMC
    1. Salonia A, Capogrosso P, Boeri L, et al (2025) European Association of Urology Guidelines on Male Sexual and Reproductive Health: 2025 Update on Male Hypogonadism, Erectile Dysfunction, Premature Ejaculation, and Peyronie's Disease. Eur Urol 7:S0302-2838(25)00211-8. https://doi.org/10.1016/j.eururo.2025.04.010 . - DOI
    1. Schwarzer U, Sommer F, Klotz T et al (2001) The prevalence of Peyronie’s disease: results of a large survey. BJU Int 88:727–730. https://doi.org/10.1046/j.1464-4096.2001.02436.x - DOI - PubMed
    1. Mulhall JP, Creech SD, Boorjian SA et al (2004) Subjective and objective analysis of the prevalence of Peyronie’s disease in a population of men presenting for prostate cancer screening. J Urol 171:2350–2353. https://doi.org/10.1097/01.ju.0000127744.18878.f1 - DOI - PubMed

LinkOut - more resources